UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 43

Sortiert nach

Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples

PloS one, 2016-12, Vol.11 (12), p.e0165109-e0165109

2016

Volltextzugriff (PDF)

Phase I/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies

Annals of nuclear medicine, 2019-02, Vol.33 (2), p.119-127

2019

Volltextzugriff (PDF)

Effectiveness of a Walking Program Involving the Hybrid Assistive Limb Robotic Exoskeleton Suit for Improving Walking Ability in Stroke Patients: Protocol for a Randomized Controlled Trial

JMIR research protocols, 2019-10, Vol.8 (10), p.e14001-e14001

2019

Volltextzugriff (PDF)

Moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial

Journal of radiation research, 2024-05, Vol.65 (3), p.402-407

2024

Volltextzugriff (PDF)

YM‐53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species

British journal of pharmacology, 2000-09, Vol.131 (1), p.63-70

2000

Volltextzugriff (PDF)

Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody

Journal of neuro-oncology, 2018-07, Vol.138 (3), p.581-589

2018

Volltextzugriff (PDF)

Comparative Studies of a Humanized Anti-glycoprotein IIb/IIIa Monoclonal Antibody, YM337, and Abciximab on in Vitro Antiplatelet Effect and Binding Properties

Biological and Pharmaceutical Bulletin, 2002, Vol.25(8), pp.1006-1012

2002

Volltextzugriff (PDF)

PHARMACOLOGICAL PROFILE OF ORALLY ADMINISTERED YM087, A VASOPRESSIN ANTAGONIST, IN CONSCIOUS RATS

Clinical and experimental pharmacology & physiology, 1999-05, Vol.26 (5-6), p.399-403

1999

Volltextzugriff (PDF)

Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89 Zr-Df-IAB2M anti-PSMA minibody

Journal of neuro-oncology, 2018-07, Vol.138 (3), p.581

2018

Volltextzugriff (PDF)

Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time

European journal of pharmacology, 1998-07, Vol.352 (1), p.59-63

1998

Volltextzugriff (PDF)

Phase I/IIa PET imaging study with 89 zirconium labeled anti-PSMA minibody for urological malignancies

Annals of nuclear medicine, 2019-02, Vol.33 (2), p.119

2019

Volltextzugriff (PDF)

Species specificity in the blood cholesterol‐lowering effect of YM‐16638

British journal of pharmacology, 1996-05, Vol.118 (1), p.174-178

1996

Volltextzugriff (PDF)

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V 1A and V 2 receptor antagonist, in dogs with pacing-induced congestive heart failure

European journal of pharmacology, 1999-07, Vol.376 (3), p.239-246

1999

Volltextzugriff (PDF)

EFFECTS OF BARNIDIPINE HYDROCHLORIDE, A CALCIUM ANTAGONIST, ON ATHEROSCLEROSIS IN CHOLESTEROL-FED RABBITS

Journal of Toxicologic Pathology, 1995/03/31, Vol.8(1), pp.1-5

1995

Volltextzugriff (PDF)

Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1A/V2 receptor antagonist

Folia Pharmacologica Japonica, 1999, Vol.114(supplement), pp.113-117

1999

Volltextzugriff (PDF)

Comparison of the Anticoagulant and Antithrombotic Effects of YM-75466, a Novel Orally-Active Factor Xa Inhibitor, and Warfarin in Mice

The Japanese Journal of Pharmacology, 1998, Vol.78(2), pp.191-197

1998

Volltextzugriff (PDF)

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure

European journal of pharmacology, 1999-07, Vol.376 (3), p.239-246

1999

Volltextzugriff (PDF)

Pharmacological Properties of YM17E, an Acyl-CoA:Cholesterol Acyltransferase Inhibitor, and Diarrheal Effect in Beagle Dogs

Japanese journal of pharmacology, 1997, Vol.73 (1), p.41-50

1997

Volltextzugriff (PDF)

Pharmacological Properties of YM17E, an Acyl-CoA: Cholesterol Acyltransferase Inhibitor, and Diarrheal Effect in Beagle Dogs

Japanese journal of pharmacology, 1997, Vol.73 (1), p.41-50

1997

Volltextzugriff (PDF)

Cholesterol-lowering effect of YM-16638 in cynomolgus monkeys

Drug development research, 1996-06, Vol.38 (2), p.86-92

1996

Volltextzugriff (PDF)

P-57 Antithrombotic effect of YM466, a synthesized factor Xa inhibitor, in arterio-venous shunt thrombosis model in squirrel monkeys

Japanese Journal of Pharmacology, 2002, Vol.88 (suppl.2), p.76-76

2002

Volltextzugriff (PDF)

Effects of YM087, a nonpeptide vasopressin V_1A and V_2 receptor antagonist, on binding and signal transduction in CHO cells transfected with human vasopressin receptors

Japanese Journal of Pharmacology, 1997, Vol.73 (suppl.1), p.158-158

1997

Volltextzugriff (PDF)

Effect of YM087, a vasopressin V_1A and V_2 receptor antagonist, in streptozotocin-induced diabetic rats

Japanese Journal of Pharmacology, 1997, Vol.73 (suppl.2), p.255-255

1997

Volltextzugriff (PDF)

Effect of YM087, a vasopressin V1A and V2 receptor antagonist, in streptozotocin-induced diabetic rats

Japanese journal of pharmacology, 1997, Vol.73, p.255-255

1997

Volltextzugriff (PDF)

Pharmacological Properties of YM 17E, an Acyl-CoA: Cholesterol Acyltransferase Inhibitor, and Diarrheal Effect in Beagle Dogs

The Japanese Journal of Pharmacology, 1997/01/01, Vol.73(1), pp.41-50

1997

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(43)

Sprache

Englisch
(38)
Japanisch
(24)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples

Phase I/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies

Effectiveness of a Walking Program Involving the Hybrid Assistive Limb Robotic Exoskeleton Suit for Improving Walking Ability in Stroke Patients: Protocol for a Randomized Controlled Trial

Moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial

YM‐53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species

Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody

Comparative Studies of a Humanized Anti-glycoprotein IIb/IIIa Monoclonal Antibody, YM337, and Abciximab on in Vitro Antiplatelet Effect and Binding Properties

PHARMACOLOGICAL PROFILE OF ORALLY ADMINISTERED YM087, A VASOPRESSIN ANTAGONIST, IN CONSCIOUS RATS

Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89 Zr-Df-IAB2M anti-PSMA minibody

Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time

Phase I/IIa PET imaging study with 89 zirconium labeled anti-PSMA minibody for urological malignancies

Species specificity in the blood cholesterol‐lowering effect of YM‐16638

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V 1A and V 2 receptor antagonist, in dogs with pacing-induced congestive heart failure

EFFECTS OF BARNIDIPINE HYDROCHLORIDE, A CALCIUM ANTAGONIST, ON ATHEROSCLEROSIS IN CHOLESTEROL-FED RABBITS

Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1A/V2 receptor antagonist

Comparison of the Anticoagulant and Antithrombotic Effects of YM-75466, a Novel Orally-Active Factor Xa Inhibitor, and Warfarin in Mice

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure

Pharmacological Properties of YM17E, an Acyl-CoA:Cholesterol Acyltransferase Inhibitor, and Diarrheal Effect in Beagle Dogs

Pharmacological Properties of YM17E, an Acyl-CoA: Cholesterol Acyltransferase Inhibitor, and Diarrheal Effect in Beagle Dogs

Cholesterol-lowering effect of YM-16638 in cynomolgus monkeys

P-57 Antithrombotic effect of YM466, a synthesized factor Xa inhibitor, in arterio-venous shunt thrombosis model in squirrel monkeys

Effects of YM087, a nonpeptide vasopressin V_1A and V_2 receptor antagonist, on binding and signal transduction in CHO cells transfected with human vasopressin receptors

Effect of YM087, a vasopressin V_1A and V_2 receptor antagonist, in streptozotocin-induced diabetic rats

Effect of YM087, a vasopressin V1A and V2 receptor antagonist, in streptozotocin-induced diabetic rats

Pharmacological Properties of YM 17E, an Acyl-CoA: Cholesterol Acyltransferase Inhibitor, and Diarrheal Effect in Beagle Dogs

Suchergebnisse filtern